Welcome to LookChem.com Sign In|Join Free

CAS

  • or

875573-66-3

Post Buying Request

875573-66-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (7a,17b)-7-(9-Bromononyl)-estra-1,3,5(10)-triene-3,17-diol 17-acetate Manufacturer/High quality/Best price/In stock

    Cas No: 875573-66-3

  • USD $ 3.0-3.0 / Kilogram

  • 1 Kilogram

  • 1-100 Metric Ton/Month

  • Dayang Chem (Hangzhou) Co.,Ltd.
  • Contact Supplier
  • High quality Estra-1,3,5(10)-Triene-3,17-Diol,7-(9-Bromononyl)-,17-Acetate,(7A,17B)- supplier in China

    Cas No: 875573-66-3

  • No Data

  • 1 Metric Ton

  • 30 Metric Ton/Month

  • Simagchem Corporation
  • Contact Supplier

875573-66-3 Usage

General Description

(7a,17b)-7-(9-Bromononyl)-estra-1,3,5(10)-triene-3,17-diol 17-acetate, also known as tibolone, is a synthetic steroid hormone that is used for hormone replacement therapy in menopausal women. It is a derivative of the hormone progesterone and has both estrogenic, progestogenic, and androgenic properties. Tibolone is primarily used to alleviate menopausal symptoms such as hot flashes and vaginal dryness, and it also helps to prevent bone loss and reduce the risk of fractures in postmenopausal women. Additionally, tibolone has been found to have beneficial effects on mood and sexual function in menopausal women.

Check Digit Verification of cas no

The CAS Registry Mumber 875573-66-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,5,5,7 and 3 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 875573-66:
(8*8)+(7*7)+(6*5)+(5*5)+(4*7)+(3*3)+(2*6)+(1*6)=223
223 % 10 = 3
So 875573-66-3 is a valid CAS Registry Number.

875573-66-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name [(7R,8R,9S,13S,14S,17S)-7-(9-bromononyl)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate

1.2 Other means of identification

Product number -
Other names (7a,17b)-7-(9-Bromononyl)-estra-1,3,5(10)-triene-3,17-diol 17-acetate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:875573-66-3 SDS

875573-66-3Synthetic route

(+)-3-oxo-(7α)-[9-bromononyl]estr-4-en-17β-ylacetate
875573-63-0

(+)-3-oxo-(7α)-[9-bromononyl]estr-4-en-17β-ylacetate

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
With lithium bromide; copper(ll) bromide In acetonitrile at 20℃; for 2h; Inert atmosphere; Schlenk technique;77%
With lithium bromide; copper(ll) bromide In acetonitrile at 20℃; for 7h;
With lithium bromide; copper(ll) bromide In acetonitrile at 20℃; for 3h; Large scale;
9-bromo-1-nonene
89359-54-6

9-bromo-1-nonene

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: Schwartz's reagent / dichloromethane / 0.33 h / 20 °C / Inert atmosphere; Schlenk technique
1.2: 0.17 h / 20 °C / Inert atmosphere; Schlenk technique
1.3: 20 °C / Inert atmosphere; Schlenk technique
2.1: lithium bromide; copper(ll) bromide / acetonitrile / 2 h / 20 °C / Inert atmosphere; Schlenk technique
View Scheme
6-dehydro-19-nortestosterone acetate
2590-41-2

6-dehydro-19-nortestosterone acetate

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: Schwartz's reagent / dichloromethane / 0.33 h / 20 °C / Inert atmosphere; Schlenk technique
1.2: 0.17 h / 20 °C / Inert atmosphere; Schlenk technique
1.3: 20 °C / Inert atmosphere; Schlenk technique
2.1: lithium bromide; copper(ll) bromide / acetonitrile / 2 h / 20 °C / Inert atmosphere; Schlenk technique
View Scheme
C30H46O6S

C30H46O6S

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
Stage #1: C30H46O6S With hydrogen bromide In acetonitrile at 20 - 25℃; for 1h;
Stage #2: With lithium hydroxide In water; acetonitrile at 50 - 60℃; for 2h; Reagent/catalyst; Temperature;
10.1 g
9-bromononan-1-ol
55362-80-6

9-bromononan-1-ol

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: 1H-imidazole; formaldehyd / toluene / 5 h / 0 - 5 °C / Large scale
2.1: magnesium / tetrahydrofuran / 4.33 h / 50 - 65 °C / Inert atmosphere; Large scale
2.2: 1 h / -30 - -15 °C / Inert atmosphere; Large scale
3.1: triphenylphosphine; bromine / dichloromethane / 3 h / -10 - 25 °C / Inert atmosphere; Large scale
4.1: copper(ll) bromide; lithium bromide / acetonitrile / 3 h / 20 °C / Large scale
View Scheme
ω-bromononanyl dimethyl-tert-butylsilyl ether
149051-24-1

ω-bromononanyl dimethyl-tert-butylsilyl ether

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: magnesium / tetrahydrofuran / 4.33 h / 50 - 65 °C / Inert atmosphere; Large scale
1.2: 1 h / -30 - -15 °C / Inert atmosphere; Large scale
2.1: triphenylphosphine; bromine / dichloromethane / 3 h / -10 - 25 °C / Inert atmosphere; Large scale
3.1: copper(ll) bromide; lithium bromide / acetonitrile / 3 h / 20 °C / Large scale
View Scheme
7α-[9-(tert-butyldimethylsiloxy)nonyl]estr-4-ene-17β-acetate-3-one
875573-60-7

7α-[9-(tert-butyldimethylsiloxy)nonyl]estr-4-ene-17β-acetate-3-one

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: triphenylphosphine; bromine / dichloromethane / 3 h / -10 - 25 °C / Inert atmosphere; Large scale
2: copper(ll) bromide; lithium bromide / acetonitrile / 3 h / 20 °C / Large scale
View Scheme
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

C6H9F5N2S*ClH

C6H9F5N2S*ClH

(+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol
153004-31-0

(+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol

Conditions
ConditionsYield
With potassium hydroxide In water; N,N-dimethyl-formamide at 0 - 40℃; for 3.5h; Reagent/catalyst; Solvent;90%
Stage #1: (+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate; C6H9F5N2S*ClH With potassium hydroxide In N,N-dimethyl-formamide at 0 - 10℃; for 1.5h;
Stage #2: In water; N,N-dimethyl-formamide at 10 - 40℃; for 2h;
Stage #3: With acetic acid In water; ethyl acetate; N,N-dimethyl-formamide for 0.166667h; Reagent/catalyst; Solvent;
90%
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

C6H9F5N2S*ClH

C6H9F5N2S*ClH

17-O-acetyl-S-deoxo-fulvestrant
875573-69-6

17-O-acetyl-S-deoxo-fulvestrant

Conditions
ConditionsYield
Stage #1: (+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate; C6H9F5N2S*ClH With potassium hydroxide In N,N-dimethyl-formamide at 0 - 10℃; for 1.5h;
Stage #2: With acetic acid In ethyl acetate; N,N-dimethyl-formamide for 0.166667h;
85%
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

4,4,5,5,5-pentafluoro-1-pentanethiol
148757-88-4

4,4,5,5,5-pentafluoro-1-pentanethiol

17-O-acetyl-S-deoxo-fulvestrant
875573-69-6

17-O-acetyl-S-deoxo-fulvestrant

Conditions
ConditionsYield
With sodium hydroxide In N,N-dimethyl acetamide; water at 20℃; for 0.6h; Product distribution / selectivity;
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

thiourea
17356-08-0

thiourea

BrH*C29H46N2O3S

BrH*C29H46N2O3S

Conditions
ConditionsYield
In isopropyl alcohol; toluene at 80℃; for 16h;
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

7α-(9-bromononyl)estra-1,3,5(10)-triene-3,17β-diol
875573-67-4

7α-(9-bromononyl)estra-1,3,5(10)-triene-3,17β-diol

Conditions
ConditionsYield
With methanol; water; hydrogen bromide at 60℃; for 0.8h;
With hydrogen bromide In methanol at 60℃; for 2h; Temperature;4.3 g
With hydrogen bromide In methanol for 3h; Reflux; Large scale;4.8 kg
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

4,4,5,5,5-pentafluoro-1-pentanethiol
148757-88-4

4,4,5,5,5-pentafluoro-1-pentanethiol

(+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol
153004-31-0

(+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol

Conditions
ConditionsYield
In methanol at 40℃; for 2h; Inert atmosphere; Schlenk technique;596 mg
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

4,4,5,5,5-pentafluoro-1-pentanethiol
148757-88-4

4,4,5,5,5-pentafluoro-1-pentanethiol

fulvestrant
129453-61-8

fulvestrant

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: methanol / 2 h / 40 °C / Inert atmosphere; Schlenk technique
2: dihydrogen peroxide; acetic acid / water; ethyl acetate / 4 h / 40 °C / Inert atmosphere; Schlenk technique
View Scheme
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

(+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol
153004-31-0

(+)-(7α)-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrogen bromide / methanol / 3 h / Reflux; Large scale
2: sodium hydroxide / N,N-dimethyl-formamide; water / 1.5 h / 0 - 15 °C / Large scale
View Scheme
(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate
875573-66-3

(+)-(7α)-[9-bromononyl]estra-1,3,5(10)-triene-3-ol-17β-yl acetate

fulvestrant
129453-61-8

fulvestrant

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: hydrogen bromide / methanol / 3 h / Reflux; Large scale
2: sodium hydroxide / N,N-dimethyl-formamide; water / 1.5 h / 0 - 15 °C / Large scale
3: acetic acid; dihydrogen peroxide / ethyl acetate / 8 h / 20 - 30 °C / Large scale
View Scheme

875573-66-3Relevant articles and documents

Impurity control method of fulvestrant

-

, (2020/09/23)

The invention belongs to the field of pharmaceutical chemicals, and relates to a fulvestrant impurity control method, which is characterized in that from the introduction of chiral carbon to the synthesis of a fulvestrant intermediate compound represented by a formula VII-1, multi-step and step-by-step control is performed on 7beta isomer impurities, so that the 7beta isomer content of the VII-1 compound is between 0.1% and 0.3%, and finally the qualified fulvestrant bulk drug with stable quality is prepared. The impurity control method is simple to operate, low in production cost and high intotal yield, and can be applied to large-scale industrial production.

An alternative synthesis of the breast cancer drug fulvestrant (Faslodex): catalyst control over C-C bond formation

Caprioglio, Diego,Fletcher, Stephen P.

, p. 14866 - 14868 (2015/10/06)

Fulvestrant (Faslodex) was synthesized in four steps (35% overall yield) from 6-dehydronandrolone acetate. Catalyst controlled, room temperature, diastereoselective 1,6-addition of the zirconocene derived from commercially available 9-bromonon-1-ene was used in the key C-C bond forming step.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 875573-66-3